Drug Trial Radar · NCT01259492
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Last checked: Nov 19, 2026Latest source record: Oct 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
725
Actual
Start
Nov 2010
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
Conditions
- Attention Deficit/Hyperactivity Disorder
Interventions
PlaceboDrug
Placebo Comparator: Placebo
Ritalin LA 20 mgDrug
Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
Ritalin LA 30 mgDrug
Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline of Period 1 (Baseline 1) to End of Period 1 on Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score by TreatmentTime frame: Baseline 1 to End of Period 1 (Week 9)
- Change From Baseline Period 1 (Baseline 1) to End of Period 1 on Sheehan Disability Scale (SDS) Total Score by TreatmentTime frame: Baseline 1 to End of Period 1 (Week 9)
- Percentage of Participants With Treatment Failures During Period 3Time frame: Baseline Period 1 (Baseline 1) and Baseline Period 3 (Baseline 2) to End of Week 40
Locations
68 sites in 9 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Spring Valley, California
Novartis Investigative Site
Bradenton, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
West Plam Beach, Florida
Novartis Investigative Site
Libertyville, Illinois
Novartis Investigative Site
Owensboro, Kentucky
Novartis Investigative Site
Troy, Michigan
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Willingboro, New Jersey
Novartis Investigative Site
Fargo, North Dakota
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Oklahoma City, Oklahoma
Novartis Investigative Site
Philadelphia, Pennsylvania
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Bellevue, Washington
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Kessel-Lo, Belgium
Novartis Investigative Site
Mechelen, Belgium
Novartis Investigative Site
Bruges, Belgium, Belgium
Novartis Investigative Site
Heusden-Zolder, Belgium, Belgium
Novartis Investigative Site
Kortenberg, Belgium, Belgium
Novartis Investigative Site
Uccle, Belgium, Belgium
Novartis Investigative Site
Antioquia, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Santa Fe de Antioquia, Antioquia, Colombia
Novartis Investigative Site
Århus C, Denmark
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Ellwangen, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Hagen, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Homburg, Germany
Novartis Investigative Site
Landau, Germany
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.